[MOL] Haemonetics' Newest Platelet Collection Product Cleared for Market [00994] Medicine On Line

[Date Prev][Date Next][Thread Prev][Thread Next][Date Index][Thread Index]

[MOL] Haemonetics' Newest Platelet Collection Product Cleared for Marketing By FDA

Good Morning My Friends,

Thought you would like to know the following. I will be posting much in
the way of various informaiton concerning conventional and alternative
(supplemental) therapies as I have come back to much information that
has beens sent to me. HOpe it enlightens your day and provides you all
with HOpe and Love for progress in the fight to beat this disease.

BRAINTREE, Mass.--(BW HealthWire)--Oct. 1, 1998--Haemonetics Corporation
(NYSE:HAE) announced today that the Company's newest product for
collection of platelets, known as "Continuous Filtration," has been
cleared for marketing by the Food and Drug Administration. A principal
use of platelets is transfusion to cancer patients to prevent bleeding.

The Continuous Filtration device automates the collection of platelets
from volunteer blood donors, and removes potentially harmful white blood
cells ("leukocytes") from the platelets during the collection procedure.

The medical and scientific communities are agreed that white blood cells
remain in blood components may be harmful to patients who receive them,
resulting in fever, chills and a medical condition known as
Alloimmunization is an antibody reaction to transfusions which can
result in
decreased responses to subsequent platelet transfusions. On September
1998, the FDA's Blood Products Advisory Committee (BPAC) recommended
that most
types of blood components for transfusion, including platelets, be white
reduced before being transfused. The BPAC recommendation is consistent
regulatory requirements in other countries including the UK, France and

Continuous Filtration is Haemonetics' second generation white cell
technology. Clinical studies of the Continuous Filtration product, which
reviewed by FDA, established that Continuous Filtration collects a
component with remaining white cell levels well within the criteria
by FDA and European regulations for allowing a platelet to be labeled as
"Leukocyte Reduced."

Today, approximately 2.5 million units of platelets are transfused
annually in
the United States alone. Only 50-60% of these are currently white cell
using any one of a variety of means for reducing white cells. Use of
prepared by Continuous Filtration eliminates the need for hospitals who
to transfuse white cell reduced platelets to use bedside filters
applied immediately prior to transfusion). Continuous Filtration
automates the white cell reduction process and reduces the risk of

James L. Peterson, President and CEO of Haemonetics said, "As the public
continues to demand safer and higher quality blood products, Haemonetics
continue to assist the blood banking community's ability to meet this
requirement, by product innovations which improve the safety and
of the highest quality blood components."

Haemonetics is a global company engaged in the design, manufacture and
worldwide marketing of automated blood processing systems. These systems
address important medical markets: surgical blood salvage, blood
collections and plasma collections. Over sixty percent of the Company's
business is outside the United States. To learn more about Haemonetics'
products and markets, visit the Company's web site at

This is an automatically-generated notice.  If you'd like to be removed
from the mailing list, please visit the Medicine-On-Line Discussion Forum
at <http://www.meds.com/con_faq.html>, or send an email message to:
with the subject line blank and the body of the message containing the line:
unsubscribe mol-cancer your-email-address
where the phrase your-email-address is replaced with your actual email